Silica-Supported Aluminum Chloride-Assisted Solution Phase Synthesis of Pyridazinone-Based Antiplatelet Agents
摘要:
A solution phase protocol that enabled the synthesis of three diverse libraries of pyridazin-3-ones incorporating alpha,beta-unsaturated moieties at position S of the heterocyclic core has been developed using silica-supported aluminum trichloride as a heterogeneous and reusable catalyst. This robust procedure has facilitated the hit to lead process for these series of compounds and allowed the identification of new potent derivatives that elicit antiplatelet activity in the low micromolar range.
PYRIDAZINONE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS
申请人:CHIESI FARMACEUTICI S.p.A.
公开号:US20160075710A1
公开(公告)日:2016-03-17
Compounds of formula (I) described herein inhibit phosphoinositide 3-kinases (PI3K) and useful for the treatment of disorders associated with PI3K enzymes.
本文描述的化合物(I)抑制磷脂酰肌醇3-激酶(PI3K),并可用于治疗与PI3K酶相关的疾病。
Pyridazines part 41: Synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl)pyridazin-3(2H)-ones
As part of the optimization process of the lead compoundI a focussed library of diversely substituted pyridazin-3(2H)-ones containing a 3-oxo-3-phenylprop-1-en-1-yl or 3-phenylprop-2-enoyl fragment at position 5 has been obtained and evaluated as antiplatelet agents. The structural modification at positions 2, 6 and 4 of the heterocyclic moiety allowed us to obtain preliminary information on the structure-activity
PYRIDAZINONE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS
申请人:Chiesi Farmaceutici S.p.A.
公开号:EP3191491B1
公开(公告)日:2019-09-04
US9745308B2
申请人:——
公开号:US9745308B2
公开(公告)日:2017-08-29
[EN] PYRIDAZINONE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDAZINONE À TITRE D'INHIBITEURS DE PHOSPHOINOSITIDE 3-KINASES
申请人:CHIESI FARMA SPA
公开号:WO2016038140A1
公开(公告)日:2016-03-17
The invention relates to compounds of formula (I) inhibiting phosphoinositide 3-kinases (PI3K), to pharmaceutical compositions comprising them, and to therapeutic uses thereof in the treatment of disorders associated with PI3K enzymes such as respiratory diseases, allergic diseases, autoimmune diseases or inflammatory disorders.